Tocilizumab for Prevention of Respiratory Failure in Patients With Severe COVID-19 Infection
The purpose of this study is to find out whether the study drug tocilizumab is an effective treatment for COVID-19 infection.
COVID-19
DRUG: Tocilizumab
Progression of Respiratory Failure or Death, The primary endpoint for this cohort is progression of respiratory failure (binary yes/no while hospitalized). Progression of respiratory failure will be defined as a sustained increase in oxygen requirement (FiO2) or need for intubation/mechanical ventilation., 14 days
The purpose of this study is to find out whether the study drug tocilizumab is an effective treatment for COVID-19 infection.